Orvacabtagene Autoleucel (JCARH125)

Overview

JCARH125 is a CAR T-cell product that targets B-cell maturation antigen (BCMA).

SparkCures ID 308
Developed By Juno Therapeutics, a Subsidiary of Celgene
Generic Name Orvacabtagene Autoleucel (JCARH125)
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed or Refractory Multiple Myeloma
EVOLVE
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed or Refractory Multiple Myeloma
EVOLVE
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

ASCO 2020 Interim Results (EVOLVE)

May 29, 2020

  • Orva-cel's phase I/II Evolve trial now has 62 evaluable subjects, 22 of whom are said to have had a complete remission, with a further 35 in partial remission.
  • Overall Response Rate (ORR) 92%.
Read More

Resources

There are no resources, links or videos to display for this treatment.